The natural product berberine is a human prolyl oligopeptidase inhibitor

被引:78
作者
Tarrago, Teresa
Kichik, Nessim
Segui, Josep
Giralt, Ernest
机构
[1] Institut de Recerca Biomèdica de Barcelona, Parc Científic de Barcelona, 08028 Barcelona, Josep Samitier
[2] Departament de Bioquímica, Universitat de Barcelona, 08028 Barcelona, Avda. Diagonal
[3] Departament de Química Orgànica, Universitat de Barcelona, 08028 Barcelona, Martí Franqués
关键词
Berberine; Fluorine NMR spectroscopy; Prolyl oligopeptidase; Schizophrenia; Traditional Chinese medicine;
D O I
10.1002/cmdc.200600303
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus. This peptidase has been associated with schizophrenia, bipolar affective disorder, and related neuropsychiatric disorders, and therefore may have important clinical implications. Among the strategies used to find novel prolyl oligopeptidase inhibitors, traditional Chinese medicinal plants provide a rich source of unexplored compounds. We used F-19 NMR spectroscopy to search for new prolyl oligopeptidase inhibitors in a library of traditional Chinese medicine plant extracts. Several extracts were identified as powerful inhibitors of this peptidase. The alkaloid berberine was the prolyl oligopeptidase inhibitory molecule isolated from Rhizoma coptidis extract. Berberine inhibited prolyl oligopeptidose in a dose-dependent manner. As berberine is a natural compound that has been safely administered to humans, it opens up new perspectives for the treatment of neuropsychiatric diseases. The results described herein suggest that the initiation of clinical trials in patients with schizophrenia, bipolar affective disorder, or related diseases in which cognitive capabilities are affected should be undertaken with either the extract or pure BBR.
引用
收藏
页码:354 / 359
页数:6
相关论文
共 37 条
[1]
[Anonymous], 2003, INFRARED
[2]
Economic consequences of the adverse reactions related with antipsychotics:: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain [J].
Bobes, J ;
Cañas, F ;
Rejas, J ;
Mackell, J .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (08) :1287-1297
[3]
Location of a major susceptibility locus for familiar schizophrenia on chromosome 1q21-q22 [J].
Brzustowicz, LM ;
Hodgkinson, KA ;
Chow, EWC ;
Honer, WG ;
Bassett, AS .
SCIENCE, 2000, 288 (5466) :678-682
[4]
Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia [J].
Castner, SA ;
Goldman-Rakic, PS ;
Williams, GV .
PSYCHOPHARMACOLOGY, 2004, 174 (01) :111-125
[5]
How can the mood stabilizer VPA limit both mania and depression? [J].
Cheng, LL ;
Lumb, M ;
Polgár, L ;
Mudge, AW .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2005, 29 (02) :155-161
[6]
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia [J].
Floresco, SB ;
Geyer, MA ;
Gold, LH ;
Grace, AA .
SCHIZOPHRENIA BULLETIN, 2005, 31 (04) :888-894
[7]
A fast and robust 19F NMR-based method for finding new HIV-1 protease inhibitors [J].
Frutos, S ;
Tarrago, T ;
Giralt, E .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) :2677-2681
[8]
Strategy for analysis and screening of bioactive compounds in traditional Chinese medicines [J].
Huang, XD ;
Kong, LA ;
Li, X ;
Chen, XG ;
Guo, M ;
Zou, HF .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 812 (1-2) :71-84
[9]
Komatsu Y, 1996, J NEUROSCI, V16, P6342
[10]
Protective effect of oren-gedoku-to against induction of neuronal death by transient cerebral ischemia in the C57BL/6 mouse [J].
Kondo, Y ;
Kondo, F ;
Asanuma, M ;
Tanaka, K ;
Ogawa, N .
NEUROCHEMICAL RESEARCH, 2000, 25 (02) :205-209